IngredientsEscin (also spelled aescin) is a mixture of saponins with anti-inflammatory, vasoconstrictor, and vasoprotective effects found in Aesculus hippocastanum (the horse chestnut). The two spellings — escin and aescin — are used interchangeably throughout the scientific literature; neither is incorrect.
Escin is a steroidal triterpene saponin isolated from the seeds of horse chestnut (Aesculus hippocastanum L.). The saponin mixture isolated from the seeds is a pentacyclic triterpene and exists in alpha and beta forms. Aescin (escin) is more precisely a mix of the triterpene saponins alpha- and beta-aescin and cryptoaescin.
Structurally, escin consists of triterpenic sapogenins such as protoescigenin and barringtogenol, linked to a trisaccharide chain (glucose, xylose, and galactose) and esterified with organic acids like angelic and tiglic acid. The beta form is the predominant and most pharmacologically active isomer. The main components of aescin are a mixture of two triterpene saponins present in two forms, α and β, dominated by the β form.
When escin is specified without any further characterization, it refers to escin purified from Aesculus hippocastanum (such as from the seeds) and is understood to include a mixture of pentacyclic triterpenes including both alpha and beta forms and includes escin Ia, escin Ib, isoescin Ia, and isoescin Ib.
Aesculus hippocastanum L. (horse chestnut) is a Paleogene relict species endemic to small restricted regions of the Balkan Peninsula. It belongs to section Aesculus of the Aesculus genus and is the only representative of the genus in Europe. As an ornamental tree, it was popularized in Europe at the end of the 16th century, and since then has been a common sight in parks, gardens, and boulevards.
The main bioactive constituents identified include triterpene saponins (escin), flavonoids, coumarins, and proanthocyanidins. Bioflavonoids present include quercetin and kaempferol and their derivatives. Antioxidants such as proanthocyanidin and coumarins including the toxic esculin, as well as fraxin and pavietin, are also found in the Aesculus genus.
Unprocessed horse chestnut seeds contain a toxin called esculin (also spelled aesculin). This toxin may increase the risk of bleeding due to its ability to prevent blood clots from forming. The unprocessed seeds are poisonous, and symptoms associated with horse chestnut seed poisoning include vomiting, diarrhea, headache, confusion, weakness, muscle twitching, poor coordination, coma, and paralysis. Horse chestnut seeds are therefore processed to remove the toxic component, resulting in purified horse chestnut seed extract (HCSE).
Horse chestnut is a valuable medicinal plant, with various organs used in traditional and conventional medicine. The history of phytochemical studies of this plant dates back to the beginning of the 19th century.
In human herbalism since the 18th century, the bark and flowers have been employed as tonics and astringents for conditions such as fever, malaria, dysentery, rheumatism, and inflammation, often prepared as teas or decoctions.
In the 16th and 17th centuries, the tree gained momentum across Eastern and Central Europe. The Turks apparently fed the seeds to horses — not for nutrition, but to strengthen their legs and improve blood circulation, hence the "horse chestnut" tag. In early folk medicine, especially in the Balkans, seed poultices were used on swollen legs, hemorrhoids, and leg ulcers.
Extracts from the seeds of Aesculus hippocastanum have been traditionally used in China as a stomachic and analgesic agent, an anti-fever and anti-hemorrhoidal agent.
In certain regions of the Balkans, the leaves and seeds were used in the form of poultices to heal wounds and reduce inflammation. In folk medicine, the bark and leaves were often used to treat sore throats and respiratory problems.
In modern Western herbalism, horse chestnut became especially popular in Germany, integrated into phytomedicines regulated under the German Commission E. Escin was first isolated in 1953.
Aescin is the main active component in horse chestnut and is responsible for most of its medicinal properties. β-Escin, a pentacyclic triterpene saponin with aglycone moieties, is the main active compound in horse chestnut seed extract.
The main active constituents isolated from horse chestnut are aescin (comprising approximately 10% of the seed) and prosapogenin. Aescin (escin) is a mix of the triterpene saponins alpha- and beta-aescin and cryptoaescin. Specific assays have been described to quantify the aescin content of preparations, including high-pressure liquid chromatography, thin-layer chromatography, and mass spectroscopy.
Some pharmaceutical formulations use sodium aescinate (a salt form) for better water solubility, particularly in intravenous and topical applications.
Escin has been shown to inhibit the activity of hyaluronidase, an enzyme involved in proteoglycan degradation. The German Commission E monograph lists aesculus as having "anti-exudative and vascular-tightening effects." Some evidence indicates that aesculus reduces the activity of lysosomal enzymes. This reduction is intensified in chronic pathological conditions of the veins, so that the breakdown of the glycocalyx in the region of the venous walls is inhibited, thus contributing to sustained venous tone. Research has identified the enzymes inhibited by horse chestnut as glycosaminoglycans hydrolase enzymes (elastase, hyaluronidase, β-N-acetyl-glucosaminidase, β-glucuronidase, and arylsulphatase).
More recent data confirm the anti-inflammatory properties of escin in reducing vascular permeability in inflamed tissues, thereby inhibiting edema formation. The venotonic effects of escin have been demonstrated primarily by in vitro studies of isolated human saphenous veins.
Escin increases venous tone by stimulating prostaglandin F2-alpha release, improving vein wall contractility.
Escin attenuates the drop in adenosine triphosphate in venous endothelial cells during hypoxia. This attenuates the inflammation response, the attraction of neutrophils, damage to the veins, and the release of growth factors — factors that otherwise would perpetuate venous insufficiency and contribute to varicose veins.
The major mechanisms for the anti-inflammatory activities are through modulation of eicosanoids and nuclear factor-kappa B (NF-κB). By inhibiting the NF-κB pathway and reducing the release of pro-inflammatory cytokines such as TNF-α and IL-6, escin effectively exerts anti-inflammatory effects and decreases vascular permeability. Simultaneously, it activates the Nrf2 pathway to eliminate free radicals, protecting endothelial cells.
The ability of escin to prevent hypoxia-induced disruption to the normal expression and distribution of platelet endothelial cell-adhesion molecule-1 may help explain its protective effect on blood vessel permeability. This triterpene has also been found to suppress the expression of adhesion molecules on endothelial cells, prevent hypoxia-induced adhesiveness of neutrophils to endothelial cells, and inhibit HIV-1 protease.
Anti-proliferation activities occur via induction of p21 and decreased expression of cyclin D1 and anti-apoptotic members of the Bcl-2 family of proteins. Beta-aescin has been evaluated in a number of in vitro studies and animal experiments for antiproliferative, apoptotic, and growth-inhibiting activities. Reductions in the number of aberrant crypt foci, as well as decreased tumor growth, have been demonstrated in rats with induced colon cancer. These anti-cancer findings are currently limited to preclinical models.
This is the area with the strongest clinical evidence base for escin.
Seventeen randomised controlled trials were included in the Cochrane review. In all trials the extract was standardised to escin, which is the main active constituent of horse chestnut seed extract. Overall, the trials suggested an improvement in the symptoms of leg pain, oedema, and pruritus with horse chestnut seed extract when taken as capsules over two to sixteen weeks.
Six placebo-controlled studies (543 participants) reported a clear reduction of leg pain when the herbal extract was compared with placebo. Similar results were reported for oedema, leg volume, leg circumference, and pruritus.
In one controlled trial, aescin was shown to be as effective as compression therapy as an alternative to medical treatment for CVI. Escin has been shown to be safe and effective for the treatment of chronic venous insufficiency. It appears to work differently than compression therapy, suggesting that it would usefully augment this therapy.
Despite this encouraging evidence, several methodological limitations exist in the trial literature. Many studies are of relatively short duration (up to sixteen weeks), used varying formulations and dosages, and some trials were sponsored by manufacturers. The overall quality of evidence has been characterized as moderate.
In a double-blind, parallel-group, 3-arm clinical study, 300 patients with postoperative or post-traumatic soft tissue swelling (contusion, sprain, or fracture traumas) were treated for 14 days with oral escin (20 mg three times a day), placebo, or a fibrinolytic control drug (serratiopeptidase 5 mg three times a day). There was a reduction in edema in 82.3% of patients in the oral escin group compared with 75% in the fibrinolytic control group and 72.4% in the placebo group (p<0.05 for escin vs placebo by day 3).
In a separate study, treatment with escin improved post-plastering edema in 92% of patients and post-traumatic edema in 95% of patients, with the majority of the improvement occurring in the first 3 weeks of treatment. Escin also scored significantly better in subjective evaluation criteria at the end of the 14-day treatment.
Escin is a promising treatment for edema, described as a naturally derived compound with anti-edematous, angio- and endothelioprotective, anti-inflammatory, and analgesic effects. The evidence in this area is supported by multiple RCTs but many are of short duration and conducted in specific orthopedic settings.
Aescin has shown satisfactory evidence for clinically significant activity in chronic venous insufficiency, haemorrhoids, and post-operative oedema. The horse chestnut is still used to treat conditions including hemorrhoids, varicose veins, hematoma, and venous congestion. However, the evidence specifically in hemorrhoids is less extensively characterized in the high-level systematic review literature than for CVI, and the strength of this evidence is considered preliminary.
A systematic review conducted in compliance with PRISMA 2020 guidance identified 16 clinical trials matching the criteria of patients with brain edema, with escin as the intervention. The review covered 15 trials (n = 1016) with acceptable risk of bias, including participants with traumatic brain injury (10 trials; n = 574), stroke (6 trials; n = 356), and/or hypertensive encephalopathy (1 trial).
Accumulating experimental evidence suggests that intravenous administration of escin exerts potent anti-inflammatory and antiedematous effects. It can inhibit acetic acid-induced vascular permeability in an acute inflammation mouse model and granuloma formation in a subchronic inflammatory rat model. Escin injection has been widely used clinically to prevent inflammatory edema after trauma such as fracture and operation in China. The evidence in neurological applications is currently considered preliminary and derives largely from studies conducted in China using intravenous sodium aescinate formulations.
Horse chestnut seed extract is well known for its anti-edematous and anti-inflammatory medicinal properties. More recently, potential anti-carcinogenic properties have been described. Escin is also active against various types of cancer, such as lung adenocarcinoma, hepatocellular carcinoma, ovarian cancer cells, and leukemia cell models. These findings are currently limited to in vitro and animal studies; no adequate human clinical trial data supporting anti-cancer use exists at this time.
In conditions of circulatory insufficiency in the ears (inner ear disturbances), supplementation of 25 mg aescin (confounded with 450 mg troxerutin) five times daily for six weeks was associated with significant improvements in hearing. This evidence is limited by confounding with another active agent and should be considered preliminary.
Escin, the active component of Aesculus hippocastanum, is available as orally absorbable dragées and as a transdermal gel.
In modern European phytotherapy, the extract is prepared from the seeds and standardized to contain 16% to 21% aescin. This is taken orally as well as applied topically in the form of a salve, cream, or ointment.
The most common dosage of horse chestnut is 300 mg HCSE twice daily, standardized to contain 50 mg escin per dose, for a total daily dose of 100 mg escin.
The daily dose of all standardized extracts is 50 mg to 150 mg of aescin, the primary active ingredient; the daily dose of non-standardized extracts, powder, decoction, and infusion is 0.3 g to 5 g of dried seeds. The specific dose is dependent on each formulation.
In the pivotal post-traumatic edema trial, oral escin was administered at 20 mg three times a day for 14 days.
In a steady-state crossover study in 18 healthy volunteers evaluating bioavailability, the daily dose studied was 50 mg escin twice daily, administered in randomized sequence for 7 days.
The absorption of escin Ib and isoescin Ib is very poor, with oral bioavailability (F) values of <2% observed for both compounds. The two compounds were found to isomerize in vivo, wherein the conversion of escin Ib to isoescin Ib was observed.
Participants given a single oral dose of sodium escinate tablets containing 30 mg of escin saponins showed detectable levels of the four saponins in human plasma for 36 hours after dosing, with peak concentrations of the four saponins in the range of 0.38–1.8 ng/mL at approximately 2 hours after dosing.
Beta-escins cleared from human plasma more rapidly than alpha-escins.
Escin serum concentrations were lower during the second dosing interval (night) than during the first interval, probably indicating a drug-by-food interaction.
The very low oral bioavailability of individual escin isomers is a notable pharmacokinetic feature. Despite this, therapeutic effects have been consistently demonstrated in clinical trials, possibly because even low plasma concentrations are sufficient for localized vascular activity, and because the extract as a whole (containing multiple isomers) may behave differently from purified individual compounds.
The German Commission E monograph lists horse chestnut preparation as Hippocastani semen (seed). It states that a dry extract of the drug is manufactured from horse chestnut seeds (Aesculus hippocastanum L.), adjusted to a content of 16–20% triterpenoid glycosides (calculated as anhydrous escin).
Germany's Commission E officially recognizes specific preparations for venous health. Escin-containing products are marketed under brand names including Reparil® in several European countries. It is a component of several pharmaceuticals on the market, including Reparil from Madaus, Opino from Wabosan, and Venosin from Astellas, among others, in Austria.
Clinical tolerance is usually excellent. The most common adverse events in oral formulations were mild gastrointestinal disorders (constipation, diarrhea, vomiting, and nausea), headache, dizziness, flushing, itching, and fatigue. In clinical studies, escin-based gel was rated as having excellent or good tolerability by >85% of patients.
Some adverse drug reactions report that escin administered by injection has a risk of causing severe renal toxicity. High intravenous doses (>510 μg/kg) or concurrent nephrotoxic drugs (e.g., aminoglycosides) increase renal risk (RR = 2.1). The proposed mechanism involves direct tubular epithelial damage and reduced renal perfusion. Elderly patients face higher acute kidney injury risk (OR = 1.8) due to age-related renal decline. This nephrotoxicity risk appears primarily associated with the intravenous route and high doses, not with oral supplementation at standard doses.
Anaphylaxis (0.2%): IgE-mediated reactions requiring immediate epinephrine and discontinuation have been reported. Hemolytic anemia (rare): saponin-induced erythrocyte membrane destabilization with prolonged high-dose intravenous use.
Aescin has been anecdotally implicated as a potential source of occupational asthma. A case was reported in which a pharmaceutical company employee developed bronchial asthma while working with plant extracts; specific inhalation challenge showed that aescin was the culprit.
Studies have indicated that herbal products containing coumarin derivatives, such as Aesculus hippocastanum, may potentiate the anticoagulant activity of warfarin by increasing the international normalized ratio. However, these coumarin derivatives (aesculin and fraxetin) are present in the bark of Aesculus hippocastanum, but not in the seeds or the seed shell, which is the part of the plant from which the active component escin is derived.
Aescin may potentially enhance the effect of blood-thinning medications (e.g., warfarin, clopidogrel, aspirin). Concomitant use should be monitored, as it may increase the risk of bleeding.
In theory, horse chestnut may increase the risk of bleeding. In addition, animal studies suggest that HCSE may cause lowered blood sugar.
The risk of kidney damage may be increased if escin is taken concurrently with medications known to be harmful to the kidneys (e.g., certain antibiotics like gentamicin).
Unprocessed horse chestnut seeds contain a toxin called esculin. This toxin may increase the risk of bleeding due to its ability to prevent blood clots from forming. The unprocessed seeds are poisonous, and symptoms associated with horse chestnut seed poisoning include vomiting, diarrhea, headache, confusion, weakness, muscle twitching, poor coordination, coma, and paralysis. Standardized commercial preparations are specifically processed to remove esculin.
Pediatric use is limited by scarce safety data; use has been reserved for severe cerebral edema under strict monitoring in this population. Data on safety in pregnancy and lactation are insufficient in the reviewed literature to make a characterization.
Health conditions that Escin may help support.
Escin (variant spelling of aescin) is the principal saponin of horse chestnut used for hemorrhoids. A double-blind, placebo-controlled RCT in 72 patients showed 82% improvement with escin versus 32% with placebo. Reviews confirm venotonic and anti-inflammatory efficacy comparable to synthetic flavonoid therapies for hemorrhoidal disease.
Body systems that Escin may help support.
Go back